Antibody C225 has Clinical Activity in Patients with Renal Cell Cancer
Treatment with combined biologic and chemotherapy utilizing either interleukin-2 or interferon is the current standard treatment with objective responses being observed in 10-15% of patients. One promising new target for treatment is the epidermal growth factor receptor which is over expressed in approximately 85% of patients with renal cell cancer. This over expression is thought to be responsible for the growth of cancer.
Suppression of this receptor could delay cancer growth and be of benefit to patients. C225 is a monoclonal antibody which specifically binds to the epidermal growth factor receptor and blocks activation of an enzyme inhibiting tumor growth in animal models.
The C225 antibody was recently evaluated as a single agent in a clinical trial of 54 patients with metastatic renal cell cancer. Three patients experienced some regression of their cancer following treatment with the C225 antibody. In all three patients the responses were seen in cancer that had spread to the lungs. Clinical trials are planned which evaluate C225 in combination with other treatments including interleukin-2 or/and interferon. (
Proceedings of American Society of Clinical Oncology, Vol 18, Abstract 1309,1999)
Copyright © 2018 CancerConnect. All Rights Reserved.